Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
| MarketCap | 2.2B |
|---|---|
| PE Ratio | |
| PEG Ratio | 0.1 |
| P/B | 12.6 |
| P/S (ttm) | 18.2 |
| Earning Growth (QoQ) | 3090% |
| Revenue Growth (QoQ) | |
| Short % | 20% |
| Held by Institutions % | 35% |
| 1 Day Vol Adjusted Return | 0.2 |
| 1 Month Vol Adjusted Return | -2.2 |
| 3 Month Vol Adjusted Return | 13.8 |
| 6 Month Vol Adjusted Return | 22.1 |
| 20 Days SMA Price ZScore | -1.0 |
| 50 Days SMA Price ZScore | -0.1 |
| 12 -26 Days PPO | -3.8 |
| 1 Month Average Short Volume Ratio | 51.1 |
| 1 Day Volume Change ZScore | 0.4 |
| 1 Month Daily Vol | 9.4 |
Stock news
The genetic testing company reported revenue of $295 million with adjusted earnings of $167.5 million, or $6.20 per share. Fulgent also provided 2021 guidance that projects 90% revenue growth this year. Most of Fulgent's tremendous revenue increase came from its COVID-19 testing business.
TEMPLE CITY, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, Marc...
Fulgent Genetics, a provider of COVID-19 testing services, beat Wall Street's fourth-quarter-earnings expectations.
The genetic-testing company provided its fourth-quarter update after the market close on Thursday. In the prior-year period, Fulgent posted a GAAP net loss of $296 million, or $0.01 per share. COVID-19 is pretty much all you need to know about Fulgent's stellar fourth-quarter results.
FLGT earnings call for the period ending December 31, 2020.
Declines for the Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) were substantial, but the indexes finished well above their worst levels. Fulgent Genetics (NASDAQ: FLGT) and T2 Biosystems (NASDAQ: TTOO) both moved sharply higher after reporting solid earnings results. Fulgent Genetics fell 8% in the regular session, but its stock had jumped 33% as of 5 p.m. EST in after-hours trading.
Shares of Fulgent Genetics (NASDAQ:FLGT) moved higher by 24.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 15400.00% year over year to $6.20, which beat the estimate of $4.05. Revenue of $294,978,000 rose by 3417.09% year over year, which beat the estimate of $199,440,000. Guidance Fulgent Genetics Sees FY21 EPS ~$12.50 Vs. $11.55 Est., Sales ~$800M Vs. $600.24M Est. Details Of The Call Date: Mar 04, 2021 Time: 04:30 PM View more ea...
Fourth Quarter 2020 Results: Record Revenue of $295.0 million, growing more than 3,400% year-over-yearRecord Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019Gross Margin improved over 8 percentage points sequentially and approximately 26 percentage points year-over-year; cost per test improved approximately 36% sequentiallyNon-COVID Revenue grew 43% year-over-yearRecord GAAP income of $166.3 million, or $6.16 per shareRecord Non-GAA...